September 2018

This letter from the Chairman and CEO of Oncology Nursing News gives an overview of the contents of the September 2018 print issue of the magazine.

Researchers exam­ined whether there were differences in resource use at end of life between patients with advanced cancer who identified goals of care focused heavily upon survival versus those who identified goals of care heavily focused on quality of life.

A novel glutaminase inhibitor, CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx) by cutting off the energy supply to tumor cells in patients with metastatic renal cell carcinoma (RCC).

The phase I open-label LIBRETTO-001 clinical trial is currently testing LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other tumors with increased RET activity.

Consistent recognition can improve morale and help organizations recruit and retain staff.

Unpaid assistants can help nurses maximize their valuable time with patients.

What to know in responding to patients’ questions about benefits, risks, and access.

How Kathleen Shannon Dorcy, PhD, RN, FAAN, became a leading voice in oncology nursing.

There are still no simple answers to the question of screening for prostate cancer.

Although JAK inhibitors are a proven effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside; in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.